Personalis is a genomic sequencing services provider with a patented ACE (Accuracy & Content Enhanced) technology that augments coverage in difficult-to-sequence regions of the genome, such as areas of high-GC content.
This ACE Platform yields the most accurate and comprehensive genetic data for pharmaceutical, biotech, clinical, and academic researchers -- providing the most reliable variant identification solution for multiple downstream applications such as:
• Immuno-Oncology
o Accurate detection of true somatic variants
o Evaluation of tumors’ mutational burden
o Identification of potential neoantigens
o Assessment of expression of immune checkpoint genes
• Cancer Clinical Trials
o Extended DNA & RNA Panels
o Tumor/normal or tumor only analysis mode
• Clinical Diagnostics
o Industry-leading diagnostic yield of the ACE Clinical Exome Test
o CLIA-licensed and CAP-accredited laboratory
Learn more at our website: http://www.personalis.com/
This ACE Platform yields the most accurate and comprehensive genetic data for pharmaceutical, biotech, clinical, and academic researchers -- providing the most reliable variant identification solution for multiple downstream applications such as:
• Immuno-Oncology
o Accurate detection of true somatic variants
o Evaluation of tumors’ mutational burden
o Identification of potential neoantigens
o Assessment of expression of immune checkpoint genes
• Cancer Clinical Trials
o Extended DNA & RNA Panels
o Tumor/normal or tumor only analysis mode
• Clinical Diagnostics
o Industry-leading diagnostic yield of the ACE Clinical Exome Test
o CLIA-licensed and CAP-accredited laboratory
Learn more at our website: http://www.personalis.com/
Location: United States, California, Menlo Park
Employees: 201-500
Phone: +1 650-324-2611
Total raised: $105M
Founded date: 2011
Investors 2
| Date | Name | Website |
| - | Lightspeed... | lsvp.com |
| - | Abingworth... | abingworth... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 19.12.2024 | - | $50M | - |
| 13.01.2015 | Series C | $33M | - |
| 07.10.2013 | Series B | $22M | - |
Mentions in press and media 17
| Date | Title | Description |
| 09.07.2025 | Personalis Expands Tempus AI Collaboration to Include Colorectal Cancer | What You Should Know: – Personalis, Inc. announced a significant expansion and extension of its strategic collaboration with Tempus AI, Inc. that adds colorectal cancer (CRC) as a new indication to their existing, exclusive commercializatio... |
| 19.12.2024 | Personalis Secures $50M from Merck, Extends Collaboration with Moderna | What You Should Know: – Personalis, Inc. (NASDAQ: PSNL) today announced agreements with long-time collaborators Merck and Moderna that accelerate the advancement of the company’s business strategy. – The company has received a $50M investme... |
| 20.11.2024 | Genetic Testing Delivers Startup Hits And Misses | 3 Shares Email Facebook Twitter LinkedIn When submitting a genetic test, one usually has a desired outcome in mind. That doesn’t mean the results will bear it out. Investing in DNA testing startups is much the same. Over the years, startup ... |
| 01.12.2022 | NGS Solutions for FFPE Materials — Maximizing Immuno-Oncology Insights with Challenging Clinical Samples, Upcoming Webinar Hosted by Xtalks | The physical and chemical modifications following formalin fixation can pose difficulties — such as DNA degradation, cross-linking and fragmentation — for NGS processes. TORONTO (PRWEB) December 01, 2022 Formalin-fixed biological specimens ... |
| 15.11.2022 | Liquid Biopsy Assays: Beyond Recurrence Detection in Post-Diagnosis Cancer Management, Upcoming Webinar Hosted by Xtalks | Personalis is committed to addressing some of the most pressing needs in the liquid biopsy space. TORONTO (PRWEB) November 15, 2022 MRD is rapidly emerging as a key biomarker in therapy development and patient care, however, key challenges ... |
| 07.10.2021 | Personalis : Prevailing Cancer Immunotherapy Challenges | Prevailing Cancer Immunotherapy Challenges Kedar Hastak, MS, PhD Manager, Field Applications Scientist Prevailing Cancer Immunotherapy Challenges In recent years, we have made great strides in our understanding of the complex interaction be... |
| 01.10.2021 | Personalis : Prevailing Cancer Immunotherapy Challenges | Prevailing Cancer Immunotherapy Challenges Kedar Hastak, MS, PhD Field Applications Scientist Prevailing Cancer Immunotherapy Challenges In recent years, we have made great strides in our understanding of the complex interaction between the... |
| 24.02.2021 | Personalis : Comprehensive Immunogenomics Profiling for the Discovery of the Next Generation of Oncology Biomarkers | Comprehensive Immunogenomics Profiling for the Discovery of the Next Generation of Oncology Biomarkers Christelle Johnson, MS, PhD Senior Field Applications Scientist Cancer Genomics & Immuno-Oncology Comprehensive Immunogenomics Profil... |
| 07.01.2021 | Tumor Mutational Burden: A Continually Evolving Biomarker for Immunotherapy | Tumor Mutational Burden: A Continually Evolving Biomarker for Immunotherapy Dan Brudzewsky, PhD Senior Field Applications Scientist - UK & Nordics Travis Yates, PhD Field Applications Scientist Tumor Mutational Burden: A Continually Evo... |
| 08.12.2020 | NeXT Liquid Biopsy: A High-Performance, Exome-Wide Liquid Biopsy Assay to Study Tumor Dynamics, Upcoming Webinar Hosted by Xtalks | To enable sensitive variant detection across 20,000 genes, this enhanced exome assay and chemistry achieves high sequencing depth of approximately 2,000x exome-wide, with additional boosted depth, 5,000x, for 247 cancer-related genes. TORON... |
Show more